KA/EN
Register
Medicines reference
Search
Search
Product

Oxtra LA

Favourites

Oxytetracycline · Fatro von Franken

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
200 mg/ml, Solution No label dose in the reference yet - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა ხანგძლივი მოქმედების
№ 1-03/41
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Oxtra LA 200 mg/ml, Solution

long-acting solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen.
Not rateable
No numerical score assigned
vetman assessment

Oxtra LA

200 mg/ml, long-acting solution for injection
Assessed clinical scopeDog · Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen. · Intramuscular
Care settingNot an established dog/cat care pathway; any exceptional proposed use would require infectious-disease justification, exact formulation review, informed consent and planned monitoring rather than extrapolation from food-animal dosing
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/41 · Verified on 15 Oct 2026 Off-label use
Not rateable

A responsible numerical score cannot be calculated for this exact canine use. Current exact-product regulatory material identifies 200 mg/ml long-acting Oxtra as an IM product for cattle, buffalo, sheep, goats, pigs and broilers, with no dog indication or regimen. One old study described pharmacokinetics of an unspecified long-acting oxytetracycline formulation at 20 mg/kg IM in healthy and Ehrlichia-infected dogs, but it did not establish equivalence to this depot, a validated clinical regimen, comparative efficacy or exact-product safety. Depot kinetics are formulation-specific, so the 5% or 100 mg/ml dog dose cannot be transferred.

The product itself is transparent and currently authorised for its listed livestock/poultry species, but that does not make it a scoreable dog/cat treatment. The correct small-animal conclusion is not a low score: it is that the exact depot lacks the species-specific dose, efficacy and safety bridge required for numerical assessment.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • This is the 200 mg/ml long-acting depot, not Oxtra 5% or Oxtra DD 100 mg/ml. Do not derive a dog/cat volume from another strength or assume that equal milligrams produce equivalent exposure; depot release is formulation-specific.
  • The exact product is authorised intramuscularly for listed livestock/poultry species, not dogs or cats. A dog/cat injection site, maximum site volume, redosing interval and reversibility of depot exposure are not established.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • No dog or cat dose is established for exact Oxtra LA. Do not use the food-animal 20-30 mg/kg depot regimen, the old unspecified canine PK dose, or the immediate-release 5%/10% schedule as a substitute for missing species-specific evidence.
Assessment sources
  1. Oxtra LA EU UPD2026
  2. Oxtra LA SmPC2026
  3. Oxtra GE register audit2026
  4. Oxtra 5% official instruction2017
  5. VMD SPC 20242024
  6. MSD tetracyclines2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen.
Not rateable
No numerical score assigned
vetman assessment

Oxtra LA

200 mg/ml, long-acting solution for injection
Assessed clinical scopeCat · Proposed off-label long-acting IM oxytetracycline treatment in dogs or cats; the exact product has no authorised dog/cat indication or regimen. · Intramuscular
Care settingNot an established dog/cat care pathway; any exceptional proposed use would require infectious-disease justification, exact formulation review, informed consent and planned monitoring rather than extrapolation from food-animal dosing
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/41 · Verified on 15 Oct 2026 Off-label use
Not rateable

A responsible numerical score cannot be calculated for this exact feline use. Current exact-product regulatory material identifies 200 mg/ml long-acting Oxtra as an IM product for food animals and broilers, with no cat indication or regimen. No applicable feline pharmacokinetic, clinical-outcome or exact-product safety study was located. Depot kinetics are formulation-specific, so neither the 5% immediate-release label nor a dog or food-animal long-acting regimen can supply the missing feline dose and benefit-risk evidence.

The product itself is transparent and currently authorised for its listed livestock/poultry species, but that does not make it a scoreable dog/cat treatment. The correct small-animal conclusion is not a low score: it is that the exact depot lacks the species-specific dose, efficacy and safety bridge required for numerical assessment.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • This is the 200 mg/ml long-acting depot, not Oxtra 5% or Oxtra DD 100 mg/ml. Do not derive a dog/cat volume from another strength or assume that equal milligrams produce equivalent exposure; depot release is formulation-specific.
  • The exact product is authorised intramuscularly for listed livestock/poultry species, not dogs or cats. A dog/cat injection site, maximum site volume, redosing interval and reversibility of depot exposure are not established.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • No dog or cat dose is established for exact Oxtra LA. Do not use the food-animal 20-30 mg/kg depot regimen, the old unspecified canine PK dose, or the immediate-release 5%/10% schedule as a substitute for missing species-specific evidence.
Assessment sources
  1. Oxtra LA EU UPD2026
  2. Oxtra LA SmPC2026
  3. Oxtra GE register audit2026
  4. Oxtra 5% official instruction2017
  5. VMD SPC 20242024
  6. MSD tetracyclines2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Oxytetracycline200 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Manufacturer
Fatro von Franken · Argentina
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა ხანგძლივი მოქმედების
№ 1-03/41
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Oxytetracycline
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25 mg/kg Dog Bacterial Infection By mouth 2 times daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxycare Tablets 250 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
10 mg/kg Dog, Cat Bacterial Infection Intramuscular / Subcutaneous once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Engemycin 10% DD solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxtra DD 100 mg/ml solution for injection for cattle, sheep, pigs, horses, dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
50 mg/kg Dog Bacterial Infection
Loading
 By mouth once, as the first dose
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Oxycare Tablets 250 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026

Known Contraindications

  • Critical
    Do not use oxytetracycline in patients with hypersensitivity to oxytetracycline or another tetracycline.
  • Critical
    Oxytetracycline crosses the placenta and is not recommended in late pregnancy. Tetracycline deposition can discolor developing teeth, cause enamel hypoplasia and reduced mineralisation, and delay fetal skeletal development. If no alternative exists, use only after a benefit-risk assessment.
  • Warning
    Avoid oxytetracycline in young growing animals because it is deposited in developing teeth and bones and can cause yellow, brown, or grey discoloration and impaired mineralisation.
  • Warning (Dog)
    Do not administer this oxytetracycline formulation intravenously to dogs. Use only a route authorised for the selected product.
  • Warning (Cat)
    Do not administer this oxytetracycline formulation intravenously to cats. Use only a route authorised for the selected product.
  • Caution
    Use oxytetracycline cautiously in hepatic impairment. Hepatic toxicity is a rare adverse effect, and dose reduction may be necessary.
  • Caution
    Use oxytetracycline cautiously in renal impairment; dose reduction may be necessary.

Known Drug Interactions

  • Major warning Oxytetracycline + Benzathine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Ceftriaxone
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Amoxicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Ampicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Procaine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Minor warning Oxytetracycline + Calcium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Calcium chloride
    Do not mix oxytetracycline with calcium-containing infusion solutions because they are physically incompatible.
    Recommendation: Do not mix oxytetracycline with lactated Ringer solution or run them through the same line.
  • Minor warning Oxytetracycline + Magnesium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Sucralfate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗